Department of Gastroenterology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.
Department of Clinical Biochemistry, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.
Clin Chem. 2023 Jul 5;69(7):699-710. doi: 10.1093/clinchem/hvad051.
Inflammatory bowel disease (IBD) comprises a group of chronic conditions characterized by relapsing and remitting inflammation of the gastrointestinal tract. The incidence is increasing worldwide, and the therapeutic options for management are expanding. Endoscopy is the gold standard investigation for diagnosis of IBD and for assessing mucosal healing, which is increasingly being used as a measure of disease control. However, it is an invasive procedure that is unpleasant for patients and expensive and time-consuming for hospitals. Fecal calprotectin has been shown to be an accurate surrogate marker of gastrointestinal inflammation in IBD.
Fecal calprotectin was initially used for the diagnosis of IBD but is now recognized as having a role in assisting in assessment of disease activity, prediction of relapse, and informing decisions around therapy and may help to minimize requirement for endoscopy. However, there are various preanalytical and analytical factors that can affect interpretation of the results; these need to be understood to optimize clinical care.
Preanalytical and analytical factors that can potentially influence fecal calprotectin concentrations are examined, and an overview is provided of clinical situations in which fecal calprotectin is commonly measured.
炎症性肠病（IBD）是一组以胃肠道反复发作和缓解性炎症为特征的慢性疾病。其发病率在全球范围内呈上升趋势，治疗管理的选择也在不断扩大。内镜检查是 IBD 的诊断和评估黏膜愈合的金标准，黏膜愈合越来越多地被用作疾病控制的衡量标准。然而，内镜检查是一种侵入性的程序，会给患者带来不适，也会给医院带来昂贵和耗时的负担。粪便钙卫蛋白已被证明是 IBD 胃肠道炎症的准确替代标志物。
粪便钙卫蛋白最初用于 IBD 的诊断，但现在已被认为在协助评估疾病活动度、预测复发、指导治疗决策方面具有作用，并可能有助于减少对内镜检查的需求。然而，有各种分析前和分析因素可能会影响结果的解读；需要了解这些因素，以优化临床护理。
本文检查了可能影响粪便钙卫蛋白浓度的分析前和分析因素，并概述了粪便钙卫蛋白常用于测量的临床情况。
